Full Press Release Details
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, August 9, 2022.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to helping people manage serious health conditions – such as diabetes, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) – and experience life without limits.
Our approach begins with MannKind’s signature technology comprised of dry-powder formulation capabilities and inhalation device engineering that offers rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a diverse pipeline, and a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Rose Alinaya, Investor Relations
Email: ir@mannkindcorp.com